Siplizumab
- Generic Name
- Siplizumab
- Drug Type
- Biotech
- CAS Number
- 288392-69-8
- Unique Ingredient Identifier
- KUW1QG1ZM3
- Indication
Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 18
- Registration Number
- NCT04803058
- Locations
- 🇰🇷
Samsung Medical University, Seoul, Korea, Republic of
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Dose Escalation Study in de Novo Renal Transplantation
- Conditions
- Kidney Transplantation
- Interventions
- Drug: Corticosteroids (CS)
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04311632
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Kansas University Medical Center, Kansas City, Kansas, United States
Renal Allograft Tolerance Through Mixed Chimerism
- Conditions
- End Stage Renal Disease
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT01780454
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study of MEDI 507 in the Treatment of Pediatric Patients
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00813618
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital, Birmingham, Alabama, United States
🇺🇸Hackensack U. Medical Center, Hackensack, New Jersey, United States
A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2008-12-12
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00807794
- Locations
- 🇺🇸
San Antonio Community Hospital, San Antonio, Texas, United States
🇺🇸Indiana University, Bloomington, Indiana, United States
🇺🇸University of Virginia, Charlottesville,, Virginia, United States
Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2008-12-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 17
- Registration Number
- NCT00806728
- Locations
- 🇺🇸
University Hospital-University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸University of Michigan Hospital, Ann Arbor, Michigan, United States
🇺🇸Western Pennsylvania Hospital - Western Pennsylvania Cancer Center, Pittsburgh, Pennsylvania, United States
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2008-12-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 34
- Registration Number
- NCT00806208
- Locations
- 🇺🇸
Baylor Institute of Transplant Sciences, Dallas, Texas, United States
🇺🇸Washington University Medical Center, St. Louis, Missouri, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2007-11-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 420
- Registration Number
- NCT00540618
- Locations
- 🇺🇸
The South Bend Clinic, South Bend, Indiana, United States
🇺🇸nTouch Research Corporation, San Diego, California, United States
🇺🇸Northwestern University Medical School, Chicago, Illinois, United States
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
- Conditions
- Psoriasis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00192452
- Locations
- 🇺🇸
MDS Pharma Services (US) Inc., Phoenix, Arizona, United States
🇺🇸Northwest Kinetics, Tacoma, Washington, United States
🇺🇸Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
- Conditions
- Lymphoproliferative Disorders
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2007-06-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00123942
- Locations
- 🇺🇸
National Cancer Institute/National Institutes of Health, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.